Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer

Inclusion Criteria: 1. Patients must have Advanced or recurrent esophageal cancer, and treatment has failed, or in the situation where effective therapy is not available, or has been refused due to severe adverse effects of chemotherapy 2. WHO performance status of 0 to 2 3. Age ≥ 20 years, ≤80 years 4. The patient does not need to have a measurable disease, but must have a disease that an effect judgment is possible 5. Passing from previous treatment more than two weeks. Passing from radiation therapy more than four weeks. 6. Expected survival of at least 3 months 7. WBC≥ 1,500/mm³ WBC≤ 15,000/mm³ Platelet count ≥ 50,000/mm³ Total bilirubin ≤ 3 x the institutional normal upper limits AST, ALT ≤ 3 x the institutional normal upper limits Creatinine ≤ 3 x the institutional normal upper limits 8. Patients must be HLA-A2402 9. Able and willing to give valid written informed consent Exclusion Criteria: 1. Pregnancy, Promise of the pregnancy, Hope of the pregnancy, Breastfeeding 2. Serious infections requiring antibiotics 3. Concurrent treatment with steroids or immunosuppressing agent 4. Disease to the central nervous system 5. Decision of unsuitableness by principal investigator or physician-in-charge